{"id":"mitomycin-c-sponge","safety":{"commonSideEffects":[{"rate":null,"effect":"Corneal toxicity / epithelial defects"},{"rate":null,"effect":"Hypotony (low intraocular pressure)"},{"rate":null,"effect":"Cataract formation"},{"rate":null,"effect":"Endothelial cell loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mitomycin-C is a mitomycin antibiotic that acts as a DNA alkylating agent, creating interstrand cross-links that prevent DNA replication and transcription, leading to cell death. When delivered via a sponge formulation during ophthalmic surgery, it inhibits fibroblast proliferation and collagen deposition, thereby reducing postoperative scarring and improving surgical outcomes in procedures like glaucoma filtration surgery and corneal transplantation.","oneSentence":"Mitomycin-C is an antibiotic that alkylates DNA, causing cross-linking and cell death, used topically to prevent scar tissue formation after ocular surgery.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:39.680Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of postoperative scarring in glaucoma filtration surgery"},{"name":"Prevention of scarring in corneal transplantation and refractive surgery"}]},"trialDetails":[{"nctId":"NCT07425743","phase":"NA","title":"Conventional Non-Penetrating Deep Sclerectomy Versus Modified Subflap Mattress Suture in OAG","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2022-11-07","conditions":"Open Angle Glaucoma (OAG)","enrollment":26},{"nctId":"NCT06944132","phase":"NA","title":"CsA vs MMC for Preventing Pterygium Recurrence","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-04-01","conditions":"Pterygium, Pterygium of the Conjunctiva and Cornea","enrollment":40},{"nctId":"NCT06038552","phase":"","title":"Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2002-01-01","conditions":"GIST, Malignant, Liver Metastases","enrollment":238},{"nctId":"NCT03875911","phase":"PHASE4","title":"Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2019-03-30","conditions":"Glaucoma Open-Angle Primary, Glaucoma, Open Angle Glaucoma","enrollment":19},{"nctId":"NCT03766425","phase":"EARLY_PHASE1","title":"Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.","status":"COMPLETED","sponsor":"Medical University of Lublin","startDate":"2017-06-14","conditions":"Eye Diseases, Optic Nerve Damage, Glaucoma Surgery","enrollment":64},{"nctId":"NCT02744690","phase":"NA","title":"Mitomycin C Trabeculectomy Trial for Glaucoma in Ethiopia","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2015-03-01","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT00003907","phase":"PHASE2","title":"Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-12-15","conditions":"Liver Cancer, Metastatic Cancer","enrollment":50},{"nctId":"NCT01881425","phase":"NA","title":"InnFocus MicroShunt Versus Trabeculectomy Study","status":"COMPLETED","sponsor":"InnFocus Inc.","startDate":"2015-12-15","conditions":"Primary Open Angle Glaucoma","enrollment":732},{"nctId":"NCT00666237","phase":"PHASE4","title":"Primary Tube Versus Trabeculectomy Study","status":"COMPLETED","sponsor":"University of Miami","startDate":"2008-04-01","conditions":"Glaucoma","enrollment":242},{"nctId":"NCT02030990","phase":"PHASE2, PHASE3","title":"The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements","status":"UNKNOWN","sponsor":"United States Naval Medical Center, San Diego","startDate":"2014-08","conditions":"Corneal Opacity","enrollment":300},{"nctId":"NCT02177123","phase":"NA","title":"Post Market Study of the InnFocus MicroShunt","status":"COMPLETED","sponsor":"InnFocus Inc.","startDate":"2014-04-04","conditions":"Primary Open Angle Glaucoma","enrollment":107},{"nctId":"NCT04352660","phase":"PHASE4","title":"Subconjunctival Versus Direct Mitomycin C in Trabeculectomy","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-05-23","conditions":"Open Angle Glaucoma","enrollment":100},{"nctId":"NCT04214847","phase":"NA","title":"The Outcome of Ahmed Glaucoma Valve in Difficult Glaucoma Cases","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2012-02-01","conditions":"Glaucoma, Open-Angle, Glaucoma Secondary, Glaucoma, Neovascular","enrollment":1},{"nctId":"NCT03924544","phase":"PHASE1","title":"Decorin in Sub Scleral Trabeculectomy","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2019-09-01","conditions":"Primary Open-angle Glaucoma","enrollment":52},{"nctId":"NCT00626782","phase":"PHASE2, PHASE3","title":"Lucentis Versus Mitomycin C During Glaucoma Surgery","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2008-01","conditions":"Glaucoma","enrollment":24},{"nctId":"NCT02016898","phase":"PHASE2","title":"The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device","status":"COMPLETED","sponsor":"Duke University","startDate":"2014-03","conditions":"Primary Open Angle Glaucoma","enrollment":100},{"nctId":"NCT01440751","phase":"PHASE4","title":"Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery","status":"COMPLETED","sponsor":"Aeon Astron Europe B.V.","startDate":"2011-09","conditions":"Glaucoma","enrollment":99},{"nctId":"NCT01527721","phase":"NA","title":"Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus","status":"COMPLETED","sponsor":"Democritus University of Thrace","startDate":"2010-09","conditions":"Keratoconus","enrollment":32},{"nctId":"NCT02901236","phase":"PHASE2, PHASE3","title":"Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma","status":"COMPLETED","sponsor":"Athens Vision Eye Institute","startDate":"2014-01","conditions":"Glaucoma","enrollment":40},{"nctId":"NCT01480817","phase":"PHASE2","title":"Sorafenib VS TACE in HCC Patients With Portal Vein Invasion","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2012-06","conditions":"Hepatocellular Carcinoma","enrollment":2},{"nctId":"NCT02301091","phase":"PHASE3","title":"Combine TACE and RFA Versus TACE Alone for HCC With PVTT","status":"UNKNOWN","sponsor":"Ming Zhao","startDate":"2014-10","conditions":"Hepatocellular Carcinoma","enrollment":240},{"nctId":"NCT02638376","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of the KXL System for Corneal Collagen Cross-Linking in Eyes Having Keratoconus","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2013-03","conditions":"Keratoconus, Post LASIK Keratectasia","enrollment":66},{"nctId":"NCT00538590","phase":"PHASE4","title":"Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery","status":"COMPLETED","sponsor":"Pro Top & Mediking Company Limited","startDate":"2007-07","conditions":"Open Angle Glaucoma","enrollment":20},{"nctId":"NCT00472810","phase":"PHASE3","title":"Ologen (OculusGen)-Glaucoma MMC Control in Pakistan","status":"COMPLETED","sponsor":"Pro Top & Mediking Company Limited","startDate":"2007-03","conditions":"Glaucoma, Trabeculectomy","enrollment":40},{"nctId":"NCT01174420","phase":"NA","title":"Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy: A Study in Germany","status":"UNKNOWN","sponsor":"Aeon Astron Europe B.V.","startDate":"2009-11","conditions":"Open-angle Glaucoma","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":182,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Mitomycin-C sponge","genericName":"Mitomycin-C sponge","companyName":"University of California, San Diego","companyId":"university-of-california-san-diego","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mitomycin-C is an antibiotic that alkylates DNA, causing cross-linking and cell death, delivered via a biodegradable sponge for localized tissue application. Used for Prevention of conjunctival scarring and fibrosis following ocular surgery, Adjunctive therapy in glaucoma filtration surgery, Prevention of pterygium recurrence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}